Evotec (EVT) Aktievy
Evotec SE är verksamt som partner inom läkemedelsforskning och läkemedelsutveckling för läkemedels- och bioteknikindustrin över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
EVT Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Evotec SE Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €3.40 |
| 52 veckors högsta | €7.30 |
| 52 veckors lägsta | €3.18 |
| Beta | 1.26 |
| 1 månads förändring | -4.27% |
| 3 månaders förändring | -32.99% |
| 1 års förändring | -44.56% |
| 3 års förändring | -83.67% |
| 5 års förändring | -91.99% |
| Förändring sedan börsintroduktionen | -78.39% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 04
EVT: INDiGO Platform And 2026 Guidance Will Drive Future Upside
Analysts have adjusted their price target on Evotec to €4.90 from €6.83, reflecting updated assumptions on fair value, discount rate, revenue, profit margin and future P/E expectations. What’s in the News for Evotec Niagen Bioscience selected Evotec as the contract research organization to support advancement of its oral small molecule NB4168 for Ataxia Telangiectasia, with Evotec providing pharmacokinetic and pharmacodynamic studies plus bioanalytical method validation in collaboration with NAD Pharmaceuticals.
Uppdatering av berättelse • Jul 21
EVT: Guidance Reset And Manufacturing Rollout Will Likely Constrain Future Re rating
Analysts have lowered their price target on Evotec, citing a shift to a more conservative fair value estimate, along with changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E, which together point to a reduced implied equity value in € terms. What’s in the News for Evotec Evotec reported preliminary unaudited H1 2026 figures, with Group revenues of about €300.1 million and an adjusted Group EBITDA loss of about €42.7 million, highlighting solid cash resources of about €465.6 million as of June 30, 2026.Recent updates
Uppdatering av berättelse • Aug 04
EVT: INDiGO Platform And 2026 Guidance Will Drive Future Upside
Analysts have adjusted their price target on Evotec to €4.90 from €6.83, reflecting updated assumptions on fair value, discount rate, revenue, profit margin and future P/E expectations. What’s in the News for Evotec Niagen Bioscience selected Evotec as the contract research organization to support advancement of its oral small molecule NB4168 for Ataxia Telangiectasia, with Evotec providing pharmacokinetic and pharmacodynamic studies plus bioanalytical method validation in collaboration with NAD Pharmaceuticals.Uppdatering av berättelse • Jul 21
EVT: Guidance Reset And Manufacturing Rollout Will Likely Constrain Future Re rating
Analysts have lowered their price target on Evotec, citing a shift to a more conservative fair value estimate, along with changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E, which together point to a reduced implied equity value in € terms. What’s in the News for Evotec Evotec reported preliminary unaudited H1 2026 figures, with Group revenues of about €300.1 million and an adjusted Group EBITDA loss of about €42.7 million, highlighting solid cash resources of about €465.6 million as of June 30, 2026.Uppdatering av berättelse • Jul 07
EVT: Rich P/E Will Likely Outweigh Benefits Of New Manufacturing Initiative
Analysts have raised their fair value estimate for Evotec from €4.0 to €4.5. They attribute this change to slightly adjusted discount rate assumptions, modestly higher expectations for revenue growth and profit margins, and a higher future P/E multiple in their updated models. What’s in the News for Evotec Evotec, through its Just – Evotec Biologics unit, launched J.TRAIN, a turnkey offering that lets biopharmaceutical companies deploy its proprietary continuous biologics manufacturing technology directly inside their own facilities, combining modular cleanrooms, industry-standard equipment and cGMP-compliant process automation.Uppdatering av berättelse • Jun 23
EVT: Rich P/E Expectations Will Likely Outweigh Alliance And Governance Progress
Analysts have revised their fair value estimate for Evotec to €4.0 from €4.4, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Evotec Evotec and Almirall nominated a small molecule preclinical development candidate in medical dermatology from their multi target drug discovery alliance, focused on immune mediated inflammatory skin diseases with high unmet medical need.
Uppdatering av berättelse • Jun 06
EVT: AI And Royalty Pipeline Will Support Future Earnings Upside
Analysts have slightly adjusted their outlook on Evotec, keeping the fair value estimate steady at €10.00 while fine tuning assumptions around discount rate, revenue growth, profit margin, and future P/E to reflect updated expectations for the business. What's in the News Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, to lead the integration of computational science and data driven decision making across its R&D operations, positioning AI and in silico capabilities as key parts of the company’s commercial offering.Uppdatering av berättelse • May 23
EVT: Future Milestone And Royalty Stream Will Support Earnings Upside
Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).Uppdatering av berättelse • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).Uppdatering av berättelse • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Uppdatering av berättelse • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).Uppdatering av berättelse • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.Uppdatering av berättelse • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.Uppdatering av berättelse • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.Uppdatering av berättelse • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).Uppdatering av berättelse • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.Uppdatering av berättelse • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.Uppdatering av berättelse • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.Uppdatering av berättelse • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Uppdatering av berättelse • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
Ny berättelse • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Analysartikel • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...Analysartikel • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Analysartikel • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Analysartikel • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...Analysartikel • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktieägarnas avkastning
| EVT | DE Life Sciences | DE Marknad | |
|---|---|---|---|
| 7D | -11.6% | -3.4% | -0.9% |
| 1Y | -44.6% | 4.1% | 2.2% |
Avkastning vs industri: EVT presterade sämre än German Life Sciences branschen som gav 4.1 % under det senaste året.
Avkastning vs Marknaden: EVT presterade sämre än German marknaden som gav 2.2 % under det senaste året.
Prisvolatilitet
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stabil aktiekurs: EVT s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: EVT s veckovolatilitet ( 9% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av German aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1993 | 4,461 | Christian Wojczewski | www.evotec.com |
Evotec SE är verksamt som partner för läkemedelsforskning och utveckling inom läkemedels- och bioteknikindustrin över hela världen. Verksamheten bedrivs inom två segment, Shared R&D och Just Evotec Biologics. Företaget utvecklar läkemedelsprodukter inom olika terapeutiska områden, såsom onkologi, autoimmuna sjukdomar, cancer, diabetes, hjärtsvikt, fibros, immunologi, smärta och inflammation, infektions-, njur-, lever-, sällsynta, respiratoriska, fibrotiska och metaboliska sjukdomar, sjukdomar i centrala nervsystemet (CNS) och hjärtmetabolism samt djur- och kvinnohälsa.
Evotec SE Sammanfattning av grunderna
| EVT grundläggande statistik | |
|---|---|
| Börsvärde | €590.13m |
| Vinst(TTM) | -€197.05m |
| Intäkter(TTM) | €717.28m |
0.8x
P/S-förhållande-3.1x
P/E-förhållandeÄr EVT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| EVT resultaträkning (TTM) | |
|---|---|
| Intäkter | €717.28m |
| Kostnad för intäkter | €656.57m |
| Bruttovinst | €60.71m |
| Övriga kostnader | €257.76m |
| Intäkter | -€197.05m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Nov 05, 2026
| Vinst per aktie (EPS) | -1.11 |
| Bruttomarginal | 8.46% |
| Nettovinstmarginal | -27.47% |
| Skuld/egenkapitalförhållande | 47.7% |
Hur har EVT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/19 21:09 |
| Aktiekurs vid dagens slut | 2026/08/19 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Evotec SE bevakas av 24 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |